A new study suggests that pediatric patients with beta-thalassemia major (BTM) may be at risk of both bleeding and thrombosis due to a derangement of hemostatic parameters that can exist apart from hepatic iron overload, and also that there may be a balance between these risks in patients at an...
research News
Ghent, Belgium – Researchers at the VIB-UGent Center for Medical Biotechnology have discovered a promising strategy to improve treatment responses in multiple myeloma patients by blocking a protein that plays a key role in drug resistance. The study, published in Pharmacological Research, offers a potential new strategy to improve outcomes...
Plymouth, UK – Drugs developed to fight blood and other cancers could also help improve the efficiency of radiotherapy in the most commonly diagnosed low-grade brain tumour in adults, a new study has found. Meningioma account for approximately 36% of all primary brain tumours. The majority are successfully treated by...
Boston, Mass. – Like a criminal entering a witness protection program, cancer cells can shed their past and take on a new identity. Detecting such an identity-switch is particularly challenging when metastatic castration-resistant prostate cancer (CRPC) advances from adenocarcinoma to neuroendocrine prostate cancer (NEPC), a very difficult cancer to treat....
Amsterdam, July 22, 2024 – To date Parkinson’s disease (PD) is diagnosed clinically and rather late in the course of the disease. There is an urgent need to find an objective, quantifiable biomarker for the diagnosis of this highly prevalent movement disorder. Researchers have now found initial evidence that a...
On the one hand, blood vessels supply tumors with nutrients and, on the other, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a distant organ is promoted by factors whose production is induced by the primary tumor itself. Scientists from the German Cancer...
NORTH CHICAGO, Ill. — BLR Bio, an early stage biotech company in Rosalind Franklin University’s Helix 51 biomedical incubator, released new data on its novel cancer therapy recently at the 7th annual Labroots Drug Discovery and Development conference. The data points to a promising strategy to boost the effectiveness of...
SAN MATEO, Calif. — Bluejay Therapeutics, Inc., a private clinical-stage biopharmaceutical company focused on viral and liver diseases, today announced the European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to BJT-778 for the treatment of Chronic Hepatitis Delta Virus (HDV) infection. BJT-778 is a high-potency, fully human immunoglobulin...
Oxford, UK – Enara Bio today announced that Boehringer Ingelheim has exercised its option to license a number of cancer antigens discovered and validated through the ongoing collaboration using Enara Bio’s Dark Antigen discovery platform, EDAPT®. This licensing event is a major milestone in the strategic collaboration between the companies...
Ingelheim am Rhein, Germany – Boehringer Ingelheim on Wednesday announced a multi-target collaboration agreement with Chinese biotech Suzhou Ribo Life Science and its Swedish unit Ribocure Pharmaceuticals to develop siRNA-based treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis. The companies did not disclose what targets they would focus on, nor did...